a2 Milk Shares Continue To Bounce as $300 Million Special Dividend Announced

The a2 Milk Company shares (ASX: A2M) jumped 3.65% today, capping a remarkable 33% rally through June, after securing pivotal Chinese regulatory approval that triggered a fully franked NZ$300 million special dividend for shareholders.

The company announced the special dividend today, further boosting a2 Milk shareholders, and extending a month-long rally that has added roughly one-third to the company’s market capitalisation. The stock’s momentum accelerated following confirmation from China’s State Administration for Market Regulation (SAMR) that two infant formula product registrations linked to the company’s Pokeno manufacturing facility can now transition to the a2 brand.

The dividend announcement, which equates to 41.36 cents per share with a franking credit of 17.72 cents, sets key dates that will drive near-term trading dynamics. The ex-dividend date falls on 8 July 2026, with the record date one day later on 9 July, and payment scheduled for 24 July 2026. Markets will likely see increased interest from income-focused portfolios ahead of the ex-dividend threshold.

China Regulatory Milestone

The SAMR approval represents the final regulatory hurdle in a2 Milk’s strategic repositioning around its Pokeno asset, acquired in September 2025. The green light allows the company to manufacture and sell China-label infant milk formula under its own premium a2 brand, rather than relying on third-party production arrangements that historically compressed margins and limited quality oversight.

China remains one of a2 Milk’s largest and most profitable markets, but it is also one of the most challenging from a regulatory standpoint. SAMR’s infant formula registration process is notoriously rigorous, with stringent requirements around manufacturing standards, supply chain traceability, and product testing. Successfully navigating this process strengthens a2’s competitive moat in a market where regulatory barriers have risen sharply in recent years.

The Pokeno facility, a state-of-the-art nutritional manufacturing plant in New Zealand, gives a2 Milk direct control over production of its A2 protein-only formula—a key differentiator in the premium infant nutrition segment. The acquisition was a significant capital commitment, and today’s SAMR approval validates the strategic rationale, confirming that the asset can now be fully leveraged for China-focused production.

The Board noted in its announcement that the actual dividend payment will be calculated on a gross distribution of 41.355 cents per share, with the 41.36 cent figure rounded for communication purposes. The substantial size of the capital return—NZ$300 million against a company that generated strong but volatile cash flows in recent periods—signals management confidence in the balance sheet post-acquisition and the sustainability of underlying cash generation.

What To Watch

From a capital allocation perspective, the NZ$300 million special dividend is a clear positive, returning surplus capital to shareholders while maintaining flexibility for reinvestment. However, the one-off nature of the payout means it should not be extrapolated into a recurring yield story. Adding to the bullish sentiment was a note out of Goldman Sachs with a Buy rating that we covered here this week.

Technically, the 33% rally in June has pushed the stock well above recent trading ranges, and some consolidation or profit-taking would not be surprising following such a sharp move. The ex-dividend date in early July will be a key inflection point, as dividend-chasing flows reverse and the stock adjusts for the capital distribution.

Despite the recent turnaround in sentiment, it is worth remembering that this has come off a sharp drawdown that continues to leave the A2M share price 22.6% under water YTD. There is plenty to like about the recent move, yet there remain challenges ahead.